Opexa Therapeutics Provides MS Trial Enrollment Update; 70% Of Patients Enrolled

THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), is pleased to announce the enrollment of the 126th patient in the Phase IIb “Abili-T” clinical study of Tcelna (imilecleucel-T) in patients with Secondary Progressive Multiple Sclerosis (SPMS).

Help employers find you! Check out all the jobs and post your resume.